BioXcel Therapeutics, Inc. Common Stock (BTAI) is a publicly traded Healthcare sector company. As of May 21, 2026, BTAI trades at $1.09 with a market cap of $30.59M and a P/E ratio of -0.24. BTAI moved +1.39% today. Year to date, BTAI is -39.11%; over the trailing twelve months it is -23.24%. Its 52-week range spans $1.01 to $13.28. Analyst consensus is buy with an average price target of $7.67. Rallies surfaces BTAI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own BTAI include Oaktree Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BioXcel Therapeutics, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $1.09 |
| Market Cap | $30.59M |
| P/E Ratio | -0.24 |
| EPS | $-4.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.28 |
| 52-Week Low | $1.01 |
| Volume | 477.39K |
| Avg Volume | 0 |
| Revenue (TTM) | $680.00K |
| Net Income | $-75.33M |
| Gross Margin | 36.32% |
3 analysts cover BTAI: 0 strong buy, 2 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.67.